Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, MorphoSys AG's Enterprise Value is €2,512.2 Mil.
MorphoSys AG's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was €-56.9 Mil. Therefore, MorphoSys AG's EV-to-EBIT ratio for today is -44.18.
EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA. As of today, MorphoSys AG's Enterprise Value is €2,512.2 Mil.
MorphoSys AG's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was €-51.1 Mil. Therefore, MorphoSys AG's EV-to-EBITDA ratio for today is -49.14.
EV-to-Revenue is calculated as Enterprise Value divided by its Revenue. As of today, MorphoSys AG's Enterprise Value is €2,512.2 Mil.
MorphoSys AG's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was €238.4 Mil. Therefore, MorphoSys AG's EV-to-Revenue ratio for today is 10.54.
MorphoSys AG Enterprise Value Historical Data
The historical data trend for MorphoSys AG's Enterprise Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of MorphoSys AG's Enterprise Value
For the Biotechnology subindustry, MorphoSys AG's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
MorphoSys AG's Enterprise Value Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, MorphoSys AG's Enterprise Value distribution charts can be found below:
* The bar in red indicates where MorphoSys AG's Enterprise Value falls into.
MorphoSys AG Enterprise Value Calculation
Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
MorphoSys AG's Enterprise Value for the fiscal year that ended in Dec. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MorphoSys AG (WBO:MOR) Enterprise Value Explanation
When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.
If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.
The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.
For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.
Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.
1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.
MorphoSys AG's current Enterprise Value is €2,512.2 Mil.
MorphoSys AG's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was €-56.9 Mil.
2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.
MorphoSys AG's current Enterprise Value is €2,512.2 Mil.
MorphoSys AG's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was €-51.1 Mil.
MorphoSys AG's current Enterprise Value is €2,512.2 Mil.
MorphoSys AG's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was €238.4 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MorphoSys AG Enterprise Value Related Terms
Thank you for viewing the detailed overview of MorphoSys AG's Enterprise Value provided by GuruFocus.com. Please click on the following links to see related term pages.
MorphoSys AG is a biopharmaceutical company dedicated to the discovery, development and commercialization of therapies for people living with cancer and autoimmune diseases. MorphoSys is advancing its own pipeline of new drug candidates and has created antibodies that are developed by partners in different areas of unmet medical need. Tremfya (guselkumab) - developed by Janssen Research & Development, LLC and marketed by Janssen Biotech, Inc. for the treatment of plaque psoriasis - became the first drug based on MorphoSys antibody technology to receive regulatory approval. The U.S. Food and Drug Administration granted accelerated approval of the company's proprietary product Monjuvi (tafasitamab-cxix) in combination with lenalidomide for patients with a certain type of lymphoma.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
WBO:MOR has been successfully added to your 